Chronic Low-Grade Inflammation Precedes Early Locoregional Recurrence following Mastectomy in Low-Risk Early-Stage Breast Cancer: A Longitudinal Case Report.
{"title":"Chronic Low-Grade Inflammation Precedes Early Locoregional Recurrence following Mastectomy in Low-Risk Early-Stage Breast Cancer: A Longitudinal Case Report.","authors":"Stefan Schreier, Prapaphan Budchart, Suparerk Borwornpinyo, Panuwat Lertsithichai, Prakasit Chirappapha, Wannapong Triampo","doi":"10.1159/000553558","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Early locoregional recurrence in low-risk early-stage breast cancer following mastectomy and adjuvant chemotherapy is a relatively infrequent event. Sufficient empirical evidence is sparse to support commonly accepted explanations relating to inflammation as a recurrence risk factor that precedes and likely promotes cancer recurrence evolution.</p><p><strong>Case presentation: </strong>Dynamics of circulating tumor cells, tissue change, and low-grade inflammation were recorded in a representative breast cancer survivor follow-up case having relapsed 31 months after treatment completion. Prospective longitudinal testing was conducted based on a cell-based liquid biopsy platform supporting multi-rare cell marker analysis. The study provided evidence for the inflammation theory relating to epithelial tissue inflammation detectable at baseline, steady progression in marker abnormality, and chronic low-grade systemic inflammation appearing in cyclical patterns.</p><p><strong>Conclusion: </strong>Therefore, our observations of persistent inflammation prior to relapse provide deeper insights into pathology progression and contribute to emerging data to support the inflammation hypothesis.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1610-1625"},"PeriodicalIF":0.7000,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623347/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000553558","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Early locoregional recurrence in low-risk early-stage breast cancer following mastectomy and adjuvant chemotherapy is a relatively infrequent event. Sufficient empirical evidence is sparse to support commonly accepted explanations relating to inflammation as a recurrence risk factor that precedes and likely promotes cancer recurrence evolution.
Case presentation: Dynamics of circulating tumor cells, tissue change, and low-grade inflammation were recorded in a representative breast cancer survivor follow-up case having relapsed 31 months after treatment completion. Prospective longitudinal testing was conducted based on a cell-based liquid biopsy platform supporting multi-rare cell marker analysis. The study provided evidence for the inflammation theory relating to epithelial tissue inflammation detectable at baseline, steady progression in marker abnormality, and chronic low-grade systemic inflammation appearing in cyclical patterns.
Conclusion: Therefore, our observations of persistent inflammation prior to relapse provide deeper insights into pathology progression and contribute to emerging data to support the inflammation hypothesis.